#SFHS2612118AFrance Adds Lynquera LP ADHD Medicines to Public-Sector Approved Drug List
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order adds three Lynquera LP methylphenidate extended-release medicines, in 18 mg, 36 mg, and 54 mg strengths, to the list of drugs approved for use by public institutions and public services in France. Health insurance coverage applies only for ADHD treatment in children aged 6 and over and adults, as part of broader care, when non-drug corrective measures are not enough. Treatment must be started and supervised by a doctor specialized in ADHD, such as a pediatrician, child and adolescent psychiatrist, or adult psychiatrist.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds Lynquera LP 18 mg, 36 mg, and 54 mg methylphenidate extended-release tablets to the approved public-sector medicines list
- Limits health insurance coverage to ADHD treatment in children aged 6 and over and adults when non-drug measures are insufficient
- Requires treatment to be started and supervised by a doctor specialized in ADHD
Obligations
What this law requires
Health insurance coverage for LYNQUERA LP 18 mg, 36 mg, and 54 mg methylphenidate extended-release tablets is limited to treatment of ADHD in children aged 6 years and over as part of comprehensive care, when corrective non-drug measures alone are insufficient.
Health insurance coverage for LYNQUERA LP 18 mg, 36 mg, and 54 mg methylphenidate extended-release tablets is limited to treatment of ADHD in adults as part of comprehensive care, when corrective non-drug measures alone are insufficient.
Treatment with the covered LYNQUERA LP methylphenidate medicines must be initiated and supervised by a physician specialized in ADHD treatment, such as a pediatrician, child and adolescent psychiatrist, or adult psychiatrist.